Results 171 to 180 of about 213,311 (303)

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

open access: yesObesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu   +13 more
wiley   +1 more source

Beyond BMI: The Impact of the New Lancet Commission Diagnostic Criteria on Prevalence of Obesity in the United States

open access: yesObesity, EarlyView.
ABSTRACT Objective This study compared population characteristics and overall US prevalence of obesity over time using the BMI criteria and the 2025 Lancet Commission criteria (i.e., the Excess Adiposity criteria). Methods We analyzed data from 58,053 adults aged ≥ 20 years in the National Health and Nutrition Examination Survey from 1999 to 2023.
Jennifer H. Hwang, Neda Laiteerapong
wiley   +1 more source

Association of Weight Status and Quality of Life Through Childhood and Adolescence: Australian Longitudinal Cohort Analysis

open access: yesObesity, EarlyView.
ABSTRACT Objective This study examined the relationship between health‐related quality of life (HRQoL) and weight status across the pediatric life course. Methods We analyzed data from a cohort of 9745 children from the Longitudinal Study of Australian Children, with follow‐up over 14 years.
Alison Hayes   +4 more
wiley   +1 more source

Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications

open access: yesObesity, EarlyView.
ABSTRACT Objective This study compared changes in health care costs and use across cohorts initiating four obesity medications (OMs). Methods Commercial insurance claims were used to identify new initiators of phentermine (n = 136,788), phentermine‐topiramate‐ER (n = 13,888), naltrexone‐bupropion‐SR (n = 28,712), or liraglutide (n = 49,266) for obesity.
Kristina H. Lewis   +10 more
wiley   +1 more source

Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER‐Medicare 2007–2015

open access: yesObesity, EarlyView.
ABSTRACT Objective This study evaluated the association between antiobesity medications (AOM) and incident cardiovascular disease (CVD) among older women, examining this relationship within and across survivors of obesity‐related cancers (ORCa) and age‐matched cancer‐free populations.
David S. Lopez   +10 more
wiley   +1 more source

Medicare Part D Formulary Coverage of Disease-Modifying Therapies for Multiple Sclerosis.

open access: yesJAMA Health Forum
Li P   +5 more
europepmc   +1 more source

Medicare Part D Preferred Pharmacy Networks And The Risk For Pharmacy Closure, 2014-23. [PDF]

open access: yesHealth Aff (Millwood)
Guadamuz JS   +3 more
europepmc   +1 more source

Medicare Utilization and Reimbursement Trends for Free Flaps in Otolaryngology, Plastic Surgery, and Maxillofacial Surgery

open access: yesOtolaryngology–Head and Neck Surgery, EarlyView.
Abstract Free flap procedures are important components of reconstructive surgery in otolaryngology, plastic surgery, and maxillofacial surgery. This research investigates trends in utilization, charges, and Medicare reimbursements for free flap procedures performed across these specialties.
Kyle Polen   +4 more
wiley   +1 more source

Potential Cost Savings in Medicare Part D for Otolaryngologic Medications. [PDF]

open access: yesIndian J Otolaryngol Head Neck Surg
Tripathi OB   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy